Background-The number of cardiovascular implantable electronic devices has increased progressively and has led to an increased need for transvenous lead extraction (TLE). Multiple reports of TLE procedural outcomes exist; however, data regarding postprocedural and long-term mortality are limited.
T he number of active cardiovascular implantable electronic devices (CIEDs) has increased progressively during the past decade, 1,2 with a parallel increase in the demand for transvenous lead extraction (TLE). 3 Transvenous lead extraction is associated with inherent intraprocedural risks and even mortality. Observational registries of experienced, high-volume extractionists have consistently demonstrated high success rates (Ͼ99%), with exceedingly low major complication (Ͻ1.0%) and mortality (Ͻ0.3%) rates. 4 -6 However, data regarding postprocedural and long-term mortality are limited. [7] [8] [9] This study examined the experience at a single high-volume extraction center regarding postprocedural and long-term mortality after TLE, in addition to evaluating potential correlates of mortality.
Clinical Perspective on p 257 Methods
We identified a cohort of consecutive patients undergoing TLE at a single, high-volume referral center between January 2000 and December 2010 and retrospectively analyzed patient characteristics, procedural indications, outcomes, and mortality. Indications for extraction were categorized as systemic infection (bacteremia and/or endocarditis), local infection (pocket infection or erosion), lead malfunction, CIED system upgrade, and other. Examples of indications included in the "other" category include venous thrombosis, severe chronic pain at the site of device or lead, advisory leads, and need for either radiation therapy or magnetic resonance imaging.
A stepwise approach to lead extraction was implemented in every case, with the goal of complete success using the least amount of tools, as previously described. 4 Complete removal of infected tissue and foreign material is mandatory in cases of CIED infection. If ipsilateral reimplantation is planned, ipsilateral venous access is attempted under fluoroscopic guidance, with or without the aid of intravenous contrast. If the vein is successfully cannulated and a wire could be passed into the inferior vena cava or if ipsilateral reimplantation is not planned, lead removal with simple traction is attempted. If this proves unsuccessful, the lead is cut, a locking stylet with No. 5 silk is introduced, and traction is reattempted. If lead removal still proves unsuccessful, a nonpowered or powered sheath is used. Sheath selection is determined by the operator's preference and experience. If the lead is not retrievable from the implantation vein or lead disruption occurs, transfemoral retrieval is performed.
The operator is well versed in all extraction modalities, with a large volume of experience (Ͼ100-lead extractions per year). Patient characteristics and the indications and outcomes for TLE were examined. Survival was assessed by both review of the electronic medical record and search of the Social Security Death Index for those individuals following up outside the institution. Follow-up information was available by at least one method for all individuals. For patients undergoing multiple TLE procedures, length of follow-up and outcomes are relative to most recent procedure.
Outcomes were based on the most recent Heart Rhythm Society lead management consensus 10 and defined as follows: (1) complete procedural success if all targeted leads and lead material were removed from the vascular space; (2) clinical success if all targeted leads and lead material were removed, but with retention of a small portion of the lead that does not negatively affect outcome goals; and (3) failure if neither complete procedural nor clinical success could be achieved. Major complications were defined as those that threaten life, require significant surgical intervention, cause persistent or significant disability, or result in death. Complications that do not meet the major complication criteria are classified as minor complications. 10 Means, medians, or proportions for baseline clinical variables were calculated for the entire cohort. Continuous variables were expressed as meanϮSD or median and the first and third quartiles (Q1 and Q3, respectively). Fisher exact tests were used to compare categorical variables. Continuous variables were compared across multiple groups using ANOVA. Cox regression was performed to identify correlates of mortality and to correct for possible confounders. Variables in the multivariable Cox regression model included age at extraction; sex; indication for extraction (systemic infection, local infection, lead malfunction, device upgrade, or other indication); CIED type (pacemaker, implantable cardioverter-defibrillator [ICD], or biventricular device); the presence of atrial fibrillation, diabetes mellitus, congestive heart failure, coronary artery disease, pacemaker dependence, or steroid use; renal function, as estimated by serum creatinine; number of leads extracted and lead implantation duration; the use of countertraction sheath assistance during TLE; and the presence of Ͼ1 TLE procedure. The age at extraction, serum creatinine, number of leads extracted, and implantation duration were modeled as continuous variables after the linearity assumption was tested. The TLE indication was categorized as systemic infection, local infection, lead malfunction, device system upgrade, and other TLE indications (eg, superior vena cava syndrome or advisory ICD lead). Lead malfunction was chosen arbitrarily as the reference group for the variable TLE indication. Similarly, the nominal variable, device type, was categorized as pacemaker, ICD, and cardiac resynchronization therapy (either pacemaker or defibrillator), with pacemaker arbitrarily chosen as the reference group. All tests of significance were 2 sided, and PϽ0.05 was considered significant. Statistical analysis was performed using SAS version 9.2 (SAS Institute; Cary, NC).
Results
Between January 2000 and December 2010, 1043 TLE procedures were performed in 985 patients. The cohort was 68% male, with a mean age of 62 years (range, 15-95 years). Comorbidities present were as follows: coronary heart disease, 45%; congestive heart failure, 43%; atrial fibrillation, 33%; and diabetes mellitus, 25%. The mean ejection fraction was 40Ϯ17% (median, 38%; Q1-Q3, 25%-55%), and the mean creatinine level was 1.3Ϯ0.8 mg/dL (median, 1.1 mg/dL; Q1-Q3, 0.9 -1.4 mg/dL). Pacemaker dependence was present in 36% of patients, and 35% underwent prior cardiac surgery. A comparison of baseline characteristics according to TLE indication is reported in Table 1 . Data are given as meanϮSD unless otherwise indicated. PPM indicates pacemaker; CRT-P, cardiac resynchronization therapy-pacemaker; ICD, implantable cardioverter-defibrillator; CRT-D, cardiac resynchronization therapy-defibrillator; DM, diabetes mellitus; CHF, congestive heart failure; EF, ejection fraction; CAD, coronary artery disease; AF, atrial fibrillation; TLE, transvenous lead extraction.
The most common indications were infection (50%; 18% systemic and 32% local), lead malfunction (30%), CIED system upgrade (8%), and other (12%). During the study period, 57 patients underwent repeat TLE. Indications for repeat procedures included all previously mentioned TLE indications, with 19 patients (34%) undergoing a second procedure for the same initial indication (eg, infection and infection or lead malfunction and lead malfunction). Of the 21 patients with initial infectious indications (local or systemic) for lead extraction undergoing a repeat procedure, 10 (48%) underwent another TLE procedure for infection at a mean of 21.4Ϯ22.6 months after the initial procedure (range, 1.3-52.9 months). Of the 36 repeat procedures performed for an initial indication other than infection, 10 patients (28%) underwent a subsequent lead extraction procedure for infection at a mean of 5.7Ϯ13.0 months (range, 0.9 -41.5 months). During the study period, 21 repeat procedures were performed for the removal of an advisory ICD lead (Sprint Fidelis, Medtronic, Inc; Minneapolis, MN) due to either lead malfunction or prophylactic means.
The total number of leads removed was 1951, with a mean of 1.9Ϯ0.9 leads per procedure. The mean implantation duration was 70.8Ϯ59.2 months (median, 52.9 months; Q1-Q3, 30.1-98.2 months); the oldest lead was in place for 398.0 months. Complete procedural success was achieved in 95.2% of patients, with a 99.4% clinical success rate. Extraction was achieved with simple traction in 696 leads (35.7%; Figure 1 ). Powered countertraction sheath assistance was used with the Excimer Laser System (Spectranetics; Colorado Springs, CO) in 1137 leads (58%) and the Evolution device (Cook Medical; Bloomington, IN) in 51 leads (2.6%). Transfemoral extraction with the Byrd Workstation (Cook Medical; Bloomington, IN) was used in 67 cases (3.4%). A 0.48% major complication rate was observed, and there were no procedure-related deaths. There were 5 cases of cardiac tamponade, 3 treated with pericardiocentesis and 2 requiring urgent sternotomy. Procedural characteristics are reported in Table 2 .
Patients were observed until the study end point (ie, death) was reached or a minimum of 8 months (range of follow-up, 4 days to 135.2 months). The mean follow-up was 3.4Ϯ2.7 years, and the median follow-up was 2.7 years (Q1-Q3, 1.3-5.1 years). Kaplan-Meier survival analysis of the entire cohort demonstrated a survival probability of 97.9% at 1 month, 95.8% at 3 months, 93.5% at 6 months, 91.6% at 1 year, 84.3% at 2 years, 68.6% at 5 years, and 53.2% (262 deaths) at 10 years. Five patients died in the hospital an average of 15 days after TLE (range, 4 -43 days). All 5 individuals had infectious indications for TLE (4 systemic and 1 local). Of the 4 patients with systemic infection, 3 died of multiorgan failure secondary to overwhelming sepsis with methicillin-sensitive Staphylococcus aureus. The fourth patient died of a complication of a second procedure performed during the index hospitalization (exsanguinating retroperitoneal hemorrhage after renal biopsy). The 1 patient with local CIED infection who died in the hospital succumbed to progressive heart failure 4 days after TLE.
If the survival data are divided according to lead extraction indication, a survival difference is noted among the groups. There is a marked initial decline in survival in the immediate period after lead extraction that is most pronounced in those referred for infectious indications or device system upgrade ( Figure 2 ). By breaking down the survival data by groups at different time points, it becomes apparent that early mortality is higher in certain groups. Among patients referred for lead extraction for systemic CIED-associated infection, the unadjusted 1-year mortality approaches 25% compared with a 1.6% to 2.4% 1-year mortality among patients referred for TLE for lead malfunction or other indications. In fact, patients with systemic infection had the poorest outcomes, with an unadjusted 1-month survival rate of 90.3%. In 
Discussion
Although TLE intraprocedural mortality may be low in high-volume extraction centers, postprocedural (30-day) and long-term mortality remain significant. In a large, heterogeneous, unselected cohort, we observed significant unadjusted mortality rates of 2.1% at 30 days, 4.2% at 3 months, and 8.4% at 1 year. If the survival data are further categorized according to lead extraction indication, long-term mortality after TLE is significantly higher in certain patient populations. There is a marked initial decline in survival in the immediate postoperative period that is sustained and most pronounced in those CIED patients with systemic infection. The survival curves for patients undergoing TLE for local infection and CIED system upgrade diverge at Ϸ2 years after the procedure from those after extraction for lead malfunction or other indications. In multivariable analysis, age, diabetes mellitus, serum creatinine, systemic and local infection, and device system upgrade were the strongest correlates of mortality.
These findings are consistent with and extend those from prior reports. Henrikson and colleagues 9 recently described midterm mortality rates among 67 patients undergoing TLE for infectious indications with an approximate even distribution of local and systemic infection. They observed a 30% mortality rate during the follow-up period (range, 6 -55 months). There were no procedure-related deaths and an overall mortality risk of 44% with systemic infection. On univariate analysis, bacteremia was the only correlate for mortality in this report. Our findings are in keeping with these observations and identified other correlates of mortality, including local infection, patient age, elevated serum creatinine, and the presence of diabetes mellitus. Hamid et al 7 published an article on a series of 183 patients undergoing TLE with a similar observed 30-day mortality rate of 2.7%. In contrast to our observations, Hamid et al observed a modest mortality rate on long-term follow-up of 6.6% at an average follow-up of 965 days. During univariate analysis, C-reactive protein, prior valve surgery, systemic infection, and echocardiographic evidence of vegetations were associated with increased mortality; during multivariable analysis, the only identified correlate of mortality was median C-reactive protein level, likely a result of sample size limitations. In a cohort of 100 patients with CIED-related endocarditis, Grammes et al 8 observed a 10% 30-day mortality rate, also in keeping with our experience.
High long-term mortality rates after TLE are likely a reflection of the severity of the underlying disease process and associated comorbidities. Interestingly, one strong correlate of risk is the indication for lead extraction, specifically infection (both systemic and local) and device system upgrade. The CIED infection is a class I indication for extraction and venous obstruction, with the need for system upgrade being a class IIa indication, according to the 2009 Heart Rhythm Society Expert Consensus on Transvenous Lead Extraction. 10 It is reasonable to hypothesize that the mortality rates for these extraction indications might be even higher in the absence of these recommendations. Although we do not have data regarding the time delays between diagnosis of infection and treatment (ie, TLE), another plausible hypothesis for the increased mortality rate is that the mortality was higher among patients in whom there was significant delay in the time to definitive treatment. Mortality rates in these situations may be modifiable, with early recognition and prompt treatment. The first presentation of patients with CIED infections is frequently to nonelectrophysiologists. Thus, the education of emergency department physicians, primary care providers, infectious disease specialists, and general cardiologists regarding the diagnosis of CIED infection and the need for urgent complete removal of all hardware may reduce the associated mortality risk. In addition, these findings demonstrate that, despite a successful extraction procedure, mortality remains high for CIED infection. This includes both system and local infections. This highlights the need to reduce the incidence of CIED-related infections. For example, careful consideration should be given before implanting transvenous devices in those at high risk of recurrent bacteremia and infection, such as renal dialysis patients.
Most patients (78%) undergoing "upgrade" were for cardiac resynchronization. This would result in a selection bias toward patients with advanced heart failure. Although data regarding mode of death are not available for the cohort, progressive heart failure may explain the observed increased mortality after extraction for system upgrade to biventricular devices.
Limitations
This study is a retrospective analysis and, thus, is subject to bias and the other well-known limitations of nonexperimental designs. The cohort was limited to a single, high-volume, academic center, and the experience may differ at other types of institutions. In addition, the details regarding mode of death were not available. Thus, definitive conclusions regarding the cause of the observed differences cannot be drawn.
Conclusions
With expanded CIED use and indications for device therapy, the need for device system revisions and observed complications will continue to increase in parallel. Although procedural mortality is exceedingly low at high-volume centers, postprocedural and long-term mortality remain high in certain patient populations. Specifically, patients with advanced age and those undergoing lead extraction for infectious indications and device system upgrade have significantly higher long-term mortality rates. Knowledge of these risks may help guide CIED and lead management. Future studies aimed at identifying potential interventions that modify long-term mortality are warranted.
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